Beckley Psytech is a British privately-held psychedelic drug developer focused on short-duration psychedelic therapies. Its two primary clinical programs are intranasal 5‑MeO‑DMT (BPL‑003), in a Phase IIb study targeting 225 moderate-to-severe TRD patients with a readout expected in H2 2024, and intravenous psilocin (ELE‑101), in a Phase I/IIa study with topline results expected in H1 2024. The company positions these shorter-duration candidates as potentially more scalable and efficient than longer-acting psychedelic-assisted therapies, which could improve patient access. Beckley and its partners are exploring digital patient-support tools and planning for future commercialization as part of development efforts. Financially, Beckley received a $50M strategic investment from atai—$40M primary and $10M secondary—which granted atai a 35.47% stake and board representation. The company previously raised an $80M Series B (upsized from $50M) in summer 2021. Beckley Psytech is a clinical-stage, privately held company developing a broad pipeline of psychedelic compounds to address neurological and psychiatric disorders. Its near-term clinical programs include a Phase 1b low-dose psilocybin trial in patients with SUNHA and a planned Phase 1 dose-ranging study of an intranasal 5-MeO-DMT formulation ahead of a Phase 2 trial in treatment-resistant depression. The company plans to expand its pipeline with new, unique and proprietary psychedelic compounds. Beckley Psytech leverages expertise developed over more than 20 years by the Beckley Foundation and was founded in 2019. It is based in Oxford, United Kingdom and states a vision for integrating clinically validated psychedelic medicines into modern medical practice. The company recently completed an oversubscribed Series B financing of $80 million to accelerate its clinical development programs. Beckley Psytech is a UK psychedelic medicine company and spin-out of the Beckley Foundation focused on turning psychedelic compounds into licensed pharmaceuticals. Its immediate focus is the development of 5-MeO-DMT as a treatment for neuropsychiatric diseases and the company is preparing to begin a Phase 1 clinical trial. The team also plans to explore other psychedelic agents targeting orphan diseases. The company was founded last year by Lady Amanda Feilding and CEO Cosmo Feilding Mellen and maintains a Scientific Advisory Board including Dr. Robin Carhart-Harris, Prof. Matthew Johnson and Prof. Guy Goodwin. Financially, the company has recently completed follow-on fundraising to push its drug development pipeline toward clinical trials.

Total raised

$149M

Funding rounds

3

Latest round

Equity

Latest activity

Jan 2024